IQVIA Holdings Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/16/2026)
| Balance Sheet | Total Assets | 29,944,000,000.00 | ROE | 21.72 % |
| Balance Sheet | Total Equity | 6,503,000,000.00 | ROA | 4.54 % |
| Cashflow | Capital Expenditures | -603,000,000.00 | P/FCF | 22.16 |
| Cashflow | Free Cash Flow | 2,051,000,064.00 | – | – |
| Cashflow | Operating Cash Flow | 2,654,000,000.00 | P/CF | 17.13 |
| Income | Earnings per Share (diluted) | 7.85 | Div. Yield | – |
| Income | Net Income | 1,360,000,000.00 | P/E | 33.42 |
| Income | Shares Outstanding | 169,600,000.00 | P/B | 6.99 |
| Income | Total Revenue | 16,310,000,000.00 | P/S | 2.79 |
Ratios calculated on: 10/14/2026
Company Description
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.iqvia.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more